Related references
Note: Only part of the references are listed.Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation
Dian Xiao et al.
BIOORGANIC CHEMISTRY (2021)
Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy
Lei He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Targeting cancer with antibody-drug conjugates: Promises and challenges
Alexis Q. Dean et al.
MABS (2021)
Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target
Faiza Javaid et al.
RSC CHEMICAL BIOLOGY (2021)
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
Chitra Joseph et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
David M. Goldenberg et al.
Oncotarget (2020)
Platinum-Triggered Bond-Cleavage of Pentynoyl Amide and N-Propargyl Handles for Drug-Activation
Bruno L. Oliveira et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer
Johannes F. Fahrmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer
Johannes F. Fahrmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Developing an Antibody-Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Elizabeth A. Love et al.
CHEMBIOCHEM (2019)
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates
Francesco Giansanti et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Cleavable linkers in antibody-drug conjugates
Jonathan D. Bargh et al.
CHEMICAL SOCIETY REVIEWS (2019)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Guangmin Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A thioether-directed palladium-cleavable linker for targeted bioorthogonal drug decaging
Benjamin J. Stenton et al.
CHEMICAL SCIENCE (2018)
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Raffaella Rossin et al.
NATURE COMMUNICATIONS (2018)
Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix
Remy Gebleux et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy
Nicolas Joubert et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo
Alberto Dal Corso et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates
Alberto Dal Corso et al.
BIOCONJUGATE CHEMISTRY (2017)
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Magdalena Dorywalska et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins
David J. Marshall et al.
MOLECULAR THERAPY (2016)
Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
Magdalena Dorywalska et al.
BIOCONJUGATE CHEMISTRY (2015)
Prediction of colorectal cancer diagnosis based oncirculating plasma proteins
Silvia Surinova et al.
EMBO MOLECULAR MEDICINE (2015)
Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer
Kenta Furukawa et al.
PANCREAS (2015)
Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
Elena Perrino et al.
CANCER RESEARCH (2014)
A Chemically Defined Trifunctional Antibody-Cytokine-Drug Conjugate with Potent Antitumor Activity
Thomas List et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
Pavel Strop et al.
CHEMISTRY & BIOLOGY (2013)
Acidic tumor microenvironment and pH-sensing G protein-coupled receptors
Calvin R. Justus et al.
FRONTIERS IN PHYSIOLOGY (2013)
Acid-Mediated Tumor Proteolysis: Contribution of Cysteine Cathepsins
Jennifer M. Rothberg et al.
NEOPLASIA (2013)
A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy
Goncalo J. L. Bernardes et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor Tissue
Masahiro Yasunaga et al.
BIOCONJUGATE CHEMISTRY (2011)
New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots
Masahiro Yasunaga et al.
CANCER SCIENCE (2011)
Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
Robert M. Sharkey et al.
MOLECULAR CANCER THERAPEUTICS (2011)
In Vivo Chemistry for Pretargeted Tumor Imaging in Live Mice
Raffaella Rossin et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
Andrew G. Polson et al.
CANCER RESEARCH (2009)
CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates
Serengulam V. Govindan et al.
CLINICAL CANCER RESEARCH (2009)
Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
Sung-Ju Moon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B
Andre Warnecke et al.
ARCHIV DER PHARMAZIE (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab
John F. DiJoseph et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides
U Niesner et al.
BIOCONJUGATE CHEMISTRY (2002)
Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis
Y Ino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
Share Paper
